vTv Therapeutics Inc. (NASDAQ:VTVT) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition
On February 27, 2019, vTv Therapeutics Inc. issued a press release to announce its financial results for the fiscal year ended December 31, 2018.A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
The information in this report (including Exhibit 99.1) shall not be deemed to be filed for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
vTv Therapeutics Inc. Exhibit
EX-99.1 2 vtvt-ex991_6.htm EX-99.1 vtvt-ex991_6.htm Exhibit 99.1 vTv Therapeutics Announces 2018 Fourth Quarter and Full Year Financial Results and Update HIGH POINT,…
To view the full exhibit click here
About vTv Therapeutics Inc. (NASDAQ:VTVT)
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
